5. Progressive supranuclear palsy Clinical trials / Disease details

Clinical trials : 95 /  Drugs : 119 - (DrugBank : 40) / Drug target genes : 65 - Drug target pathways : 108

  
2 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT05187546
(ClinicalTrials.gov)		February 202223/11/2021Test-retest Study With [18F]PI-2620 in PSP-RS and NDCAn Open Label, Single Center Study to Evaluate the Safety and Test-retest Characteristics of [18F]PI-2620 as PET Radioligand for Imaging Tau Deposition in the Brains of Patients With Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS) Compared to Non-demented Controls (NDC)Progressive Supranuclear PalsyDrug: [18F]-PI2620Life Molecular Imaging GmbHNULLRecruiting50 Years80 YearsAll15Phase 1Germany
2NCT04715750
(ClinicalTrials.gov)		November 12, 202011/12/2020Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific ActivityAn Open Label, Single Center Study to Evaluate the Safety and Imaging Characteristics of [18F]PI-2620 as PET Radioligand for Imaging Tau Deposition in the Brains of Patients With Mild to Moderate Alzheimer's Disease (AD) and Patients With Progressive Supranuclear Palsy (PSP) After i.v. Application of [18F]PI-2620 With High and Low Specific ActivityAlzheimer Disease;Progressive Supranuclear PalsyDrug: [18F]-PI2620Life Molecular Imaging GmbHLife Molecular Imaging SARecruiting50 Years80 YearsAll10Phase 1Germany